In conclusion, R-EPOCH could be superior to R-CHOP as a first-line regimen in DLBCL patients with high Ki-67 expression, particularly in those of low-to-intermediate IPI risk. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.